BioCentury | Jun 4, 2020
Product Development

June 3 Quick Takes: Double double for BeiGene’s Brukinsa; plus Novartis, Merck-Vaxxas, Antibe, Mirum and more

BeiGene’s BTK inhibitor gets first China approval  BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) said China’s National Medical Products Administration approved Brukinsa zanubrutinib in two cancer indications: chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma...
BC Week In Review | Nov 9, 2018
Company News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
BC Extra | Nov 7, 2018
Financial News

Mirum launches with liver disease candidates from Shire

Mirum Pharmaceuticals Inc. (San Francisco, Calif.) launched with a $120 million series A round and a license from Shire plc (LSE:SHP; NASDAQ:SHPG) to a pair of candidates to treat liver diseases. The start-up intends to...
BC Extra | Jan 19, 2018
Company News

Albireo receives $55M for elobixibat approval in Japan

Albireo Pharma Inc. (NASDAQ:ALBO) nearly doubled its cash reserves after Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Goofice elobixibat on Friday to treat chronic constipation. The approval triggered about $55 million in payments...
BioCentury | Jul 21, 2017
Finance

Itching to invest

A growing strategic interest in pruritus underlies two series C rounds with multiple new investors that were announced the week of July 17. For Trevi Therapeutics Inc. , the $50.5 million round announced July 20 is...
BioCentury | Jul 13, 2015
Finance

Mid-cap hot streak

Almost all of the biotech market cap tiers tracked by BioCentury ended the second quarter in the black. The lone exception was companies valued below $200 million, which collectively fell a median 1.2%. Big cap...
BC Week In Review | Apr 13, 2015
Clinical News

SHP625: Phase II data

Top-line data from the double-blind, U.K. Phase II IMAGO trial in 20 patients ages 1-18 with Alagille syndrome showed that once-daily oral SHP625 missed the primary endpoint of reducing fasting serum bile acid levels from...
BC Extra | Apr 10, 2015
Top Story

Priority Review erases Shire's losses on trial miss

Shire plc (LSE:SHP; NASDAQ:SHPG) turned early losses on clinical data into gains on Thursday, picking up $7.24 to $254.32 on NASDAQ after FDA accepted for filing and granted Priority Review to an NDA for lifitegrast...
BioCentury | Jul 21, 2014
Strategy

AbbVie's plan B

Clinical setbacks and a rapidly evolving HCV landscape have left AbbVie Inc. less insulated from potential biosimilar competition for blockbuster Humira adalimumab. Now that Shire plc has decided to accept AbbVie's takeout bid, the specialty...
BC Week In Review | May 19, 2014
Company News

Lumena Pharmaceuticals, Shire deal

Shire will acquire Lumena for $260 million in cash up front. Lumena will also receive an undisclosed payment for its net cash and is eligible for undisclosed milestone payments tied to clinical trials of LUM001...
Items per page:
1 - 10 of 21